NEA 17 fund tied to Korro Bio (KRRO) buys 450K shares and warrants

Rhea-AI Filing Summary

Korro Bio, Inc. insider Paul Edward Walker, a reported ten percent owner through New Enterprise Associates entities, reported net purchases of Korro Bio securities. An affiliate bought 242,945 Pre-Funded Warrants, each exercisable into one share of Common Stock at an exercise price of $0.001 per share, at a purchase price of $11.109 per warrant.

The same affiliated fund also bought 207,100 shares of Common Stock at $11.11 per share, bringing its indirect Common Stock holdings to 1,297,893 shares following the transactions. All securities are held indirectly by New Enterprise Associates 17, L.P., and Walker disclaims beneficial ownership of any portion in which he has no pecuniary interest.

The Pre-Funded Warrants are immediately exercisable but include a beneficial ownership limitation: they cannot be exercised if doing so would cause the holder and certain related parties to exceed 9.99% of Korro Bio’s outstanding Common Stock, a cap that can be adjusted up to 19.99% with 61 days’ prior notice.

Insights

Insider trading analyst

NEA 17 fund reports a sizable net share and warrant purchase in Korro Bio.

The reporting structure shows that New Enterprise Associates 17, L.P. acquired both Common Stock and Pre-Funded Warrants in Korro Bio. The total net purchase was 450,045 instruments (shares and warrant units combined), all held indirectly through the venture fund rather than personally by Paul Edward Walker.

Because these are coded as open-market or private purchases (code P) and tied to a Subscription Agreement, they indicate additional capital committed to Korro Bio by an existing large holder. Walker is a manager of the fund’s general partner and disclaims beneficial ownership where he has no pecuniary interest, so the economic exposure primarily resides with the NEA 17 fund.

The Pre-Funded Warrants are immediately exercisable at a nominal $0.001 per-share exercise price but are constrained by a 9.99% to 19.99% beneficial ownership cap. This structure can limit how quickly the fund converts warrants into common shares, meaning actual share-count changes will depend on Korro Bio’s outstanding stock and any future adjustment of that cap.

Insider Trade Summary

Net Buyer: 450,045 shares ($4,999,757)

Net Buy 2 txns

Insider Walker Paul Edward

Role 10% Owner

Bought 450,045 shs ($5.00M)

Type	Security	Shares	Price	Value
Purchase	Pre-Funded Warrants	242,945	$11.109	$2.70M
Purchase	Common Stock	207,100	$11.11	$2.30M

Holdings After Transaction: Pre-Funded Warrants — 242,945 shares (Indirect, See Note 2); Common Stock — 1,297,893 shares (Indirect, See Note 2)

Footnotes (1)

1. Acquired from the Issuer on March 10, 2026 pursuant to a Subscription Agreement dated March 9, 2026. The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest. The Pre-Funded Warrants are exercisable at any time after their issuance; provided, however, that the Pre-Funded Warrants may not be exercised to the extent such exercise would cause the number of shares of the Issuer's Common Stock owned by the holder (together with its affiliates and certain other related parties) to exceed 9.99% of the total number of shares of the Issuer's Common Stock immediately after giving effect to such exercise, which percentage may be increased or decreased at the option of the holder upon 61 days' prior notice to the Issuer, not to exceed 19.99%.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Walker Paul Edward

(Last) (First) (Middle)

2855 SAND HILL ROAD

(Street)

MENLO PARK CA 94025

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Korro Bio, Inc. [ KRRO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/10/2026		P(1)		207,100	A	$11.11	1,297,893	I	See Note 2(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Pre-Funded Warrants	$0.001	03/10/2026		P(1)		242,945		(3)	(3)	Common Stock	242,945	$11.109	242,945	I	See Note 2(2)

Explanation of Responses:

1. Acquired from the Issuer on March 10, 2026 pursuant to a Subscription Agreement dated March 9, 2026.

2. The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

3. The Pre-Funded Warrants are exercisable at any time after their issuance; provided, however, that the Pre-Funded Warrants may not be exercised to the extent such exercise would cause the number of shares of the Issuer's Common Stock owned by the holder (together with its affiliates and certain other related parties) to exceed 9.99% of the total number of shares of the Issuer's Common Stock immediately after giving effect to such exercise, which percentage may be increased or decreased at the option of the holder upon 61 days' prior notice to the Issuer, not to exceed 19.99%.

	/s/ Zachary Bambach, attorney-in-fact	03/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did Korro Bio (KRRO) report for Paul Edward Walker?

Paul Edward Walker reported net purchases in Korro Bio via an affiliated fund. New Enterprise Associates 17, L.P. acquired 242,945 Pre-Funded Warrants and 207,100 Common Shares, increasing its indirect holdings while Walker disclaims beneficial ownership where he has no pecuniary interest.

How many Korro Bio (KRRO) shares does NEA 17 hold after the reported Form 4 transactions?

After the reported transactions, New Enterprise Associates 17, L.P. holds 1,297,893 shares of Korro Bio Common Stock indirectly. It also owns 242,945 Pre-Funded Warrants, each exercisable into one additional share, subject to stated beneficial ownership limits on post-exercise holdings.

What prices were paid for the Korro Bio (KRRO) securities in this Form 4 filing?

The affiliated fund purchased Pre-Funded Warrants at $11.109 per warrant and Common Stock at $11.11 per share. Each warrant is exercisable into one share of Common Stock at a nominal additional exercise price of $0.001 per share.

Who actually holds the Korro Bio (KRRO) shares and warrants reported by Paul Edward Walker?

The securities are held by New Enterprise Associates 17, L.P., a venture fund. Paul Edward Walker is a manager of its general partner but disclaims beneficial ownership of any portion of the Korro Bio securities in which he has no pecuniary interest, under Section 16 definitions.

What are the key terms of the Korro Bio (KRRO) Pre-Funded Warrants acquired in this transaction?

The Pre-Funded Warrants are exercisable any time after issuance at an exercise price of $0.001 per share. Exercise is limited so that the holder and related parties generally cannot exceed 9.99% ownership, adjustable up to 19.99% with 61 days’ prior notice.

Was the Korro Bio (KRRO) insider purchase made on the open market or via agreement?

The filing characterizes the transactions as purchases, and a footnote explains the securities were acquired from Korro Bio on March 10, 2026 under a Subscription Agreement dated March 9, 2026, indicating a negotiated purchase rather than ordinary open-market trading.